Skip to content

Study · Not a test of the peptide alone · 2012

6 results

[Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types].

Neznamov GG, Bochkarev VK, Reutova MA, Shabanova AA, Siuniakov SA

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2012Cited by 2 (Europe PMC)

PMID22834121 (opens in a new tab)PepBankPUB-22834121
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Bromantane.

  1. 01HumanNot a test of Bromantane aloneObservational studyEfficacy outcome

    In neurasthenia patients, subjective ladasten and placebo effectiveness was higher with reduced EEG alpha activity and emotional lability/inertness.

    In plain wordsIn neurasthenia patients, both treatments received higher effectiveness ratings with reduced EEG alpha activity than with prominent alpha rhythm.

    Peptide
    Bromantane
    Outcome
    IncreaseSubjective therapeutic effectiveness by EEG/personality subgroup
    Study

    n: not reported in source

    Comparator
    patients with prominent alpha rhythm and sthenic personal traits
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    It is established that, in patients with neurasthenia characterized by reduced EEG alpha activity combined with emotional lability and inertness, the therapeutic action and effectiveness of ladasten and placebo was more robust (the subjective estimation was higher) than in patients with prominent al…
    1 context sentence
    Summary · context
    The study was focused on the clinico-pharmacological analysis of differences between subjective and objective assessment of the effects of antiasthenic drug ladasten and placebo effects in patients with neurasthenia with different individual patterns manifested in their EEG alpha rhythms and MMPI findings.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

  2. 02HumanNot a test of Bromantane aloneObservational studySafety outcome

    In neurasthenia patients, single-dose ladasten and placebo tolerability ratings were independent of EEG alpha rhythm and personality differences.

    In plain wordsIn neurasthenia patients, single-dose ladasten and placebo tolerability ratings did not depend on EEG alpha rhythm or personality differences.

    Peptide
    Bromantane
    Outcome
    No significant changeTolerability assessment by EEG/personality subgroup
    Study

    n: not reported in source

    Comparator
    patients with prominent alpha rhythm and sthenic personal traits
    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    The self-assessment of the effect of single test doses of ladasten and placebo was independent of the individual differences of EEG alpha rhythm organization and personal traits with respect to tolerability, wish to continue the treatment, activating and calming effects.
    1 context sentence
    Summary · context
    The study was focused on the clinico-pharmacological analysis of differences between subjective and objective assessment of the effects of antiasthenic drug ladasten and placebo effects in patients with neurasthenia with different individual patterns manifested in their EEG alpha rhythms and MMPI findings.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

  3. 03HumanNot a test of Bromantane aloneObservational studyOther

    In neurasthenia patients, willingness to continue ladasten and placebo was independent of EEG alpha rhythm and personality differences.

    In plain wordsIn neurasthenia patients, willingness to continue either treatment did not depend on EEG alpha rhythm or personality differences.

    Peptide
    Bromantane
    Outcome
    No significant changeWish to continue treatment by EEG/personality subgroup
    Study

    n: not reported in source

    Comparator
    patients with prominent alpha rhythm and sthenic personal traits
    Outcome group
    Patient-reported outcomes · Mental health and mood

    Source sentences

    Summary
    The self-assessment of the effect of single test doses of ladasten and placebo was independent of the individual differences of EEG alpha rhythm organization and personal traits with respect to tolerability, wish to continue the treatment, activating and calming effects.
    1 context sentence
    Summary · context
    The study was focused on the clinico-pharmacological analysis of differences between subjective and objective assessment of the effects of antiasthenic drug ladasten and placebo effects in patients with neurasthenia with different individual patterns manifested in their EEG alpha rhythms and MMPI findings.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

  4. 04HumanNot a test of Bromantane aloneObservational studyEfficacy outcome

    In neurasthenia patients, single-dose ladasten and placebo activation ratings were independent of EEG alpha rhythm and personality differences.

    In plain wordsIn neurasthenia patients, activation ratings for either treatment did not depend on EEG alpha rhythm or personality differences.

    Peptide
    Bromantane
    Outcome
    No significant changeActivating effect assessment by EEG/personality subgroup
    Study

    n: not reported in source

    Comparator
    patients with prominent alpha rhythm and sthenic personal traits
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    The self-assessment of the effect of single test doses of ladasten and placebo was independent of the individual differences of EEG alpha rhythm organization and personal traits with respect to tolerability, wish to continue the treatment, activating and calming effects.
    1 context sentence
    Summary · context
    The study was focused on the clinico-pharmacological analysis of differences between subjective and objective assessment of the effects of antiasthenic drug ladasten and placebo effects in patients with neurasthenia with different individual patterns manifested in their EEG alpha rhythms and MMPI findings.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

  5. 05HumanNot a test of Bromantane aloneObservational studyEfficacy outcome

    In neurasthenia patients, single-dose ladasten and placebo calming ratings were independent of EEG alpha rhythm and personality differences.

    In plain wordsIn neurasthenia patients, calming ratings for either treatment did not depend on EEG alpha rhythm or personality differences.

    Peptide
    Bromantane
    Outcome
    No significant changeCalming effect assessment by EEG/personality subgroup
    Study

    n: not reported in source

    Comparator
    patients with prominent alpha rhythm and sthenic personal traits
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    The self-assessment of the effect of single test doses of ladasten and placebo was independent of the individual differences of EEG alpha rhythm organization and personal traits with respect to tolerability, wish to continue the treatment, activating and calming effects.
    1 context sentence
    Summary · context
    The study was focused on the clinico-pharmacological analysis of differences between subjective and objective assessment of the effects of antiasthenic drug ladasten and placebo effects in patients with neurasthenia with different individual patterns manifested in their EEG alpha rhythms and MMPI findings.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

  6. 06HumanNot a test of Bromantane aloneObservational studyEfficacy outcome

    In neurasthenia patients, long-term ladasten and placebo ratings were higher with reduced EEG alpha rhythm and corresponded to objective psychotropic indices.

    In plain wordsIn neurasthenia patients, both treatments received higher long-term ratings with reduced EEG alpha rhythm, consistent with objective measures.

    Peptide
    Bromantane
    Outcome
    IncreaseLong-term subjective treatment assessment by EEG subgroup
    Study

    n: not reported in source

    Comparator
    patients with prominent alpha rhythm and sthenic personal traits
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    In long-term treatment, higher subjective estimations of the ladasten and placebo effect appeared in patients with reduced EEG alpha rhythm, and the difference corresponded to objective indices of the psychotropic action and effectiveness of the drug.
    1 context sentence
    Summary · context
    The study was focused on the clinico-pharmacological analysis of differences between subjective and objective assessment of the effects of antiasthenic drug ladasten and placebo effects in patients with neurasthenia with different individual patterns manifested in their EEG alpha rhythms and MMPI findings.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.